# Tolerance and Efficacy Nicotinamide (Vitamin B3) in Dominant Optic Atrophy OPA1

> **NCT06007391** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital, Angers** · enrollment: 25 (estimated)

## Conditions studied

- Nicotinamide Adverse Reaction

## Interventions

- **DRUG:** Nicotinamide

## Key facts

- **NCT ID:** NCT06007391
- **Lead sponsor:** University Hospital, Angers
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-23
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06007391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06007391, "Tolerance and Efficacy Nicotinamide (Vitamin B3) in Dominant Optic Atrophy OPA1". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06007391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*